On 30 December, China's National Medical Products Administration (NMPA) granted approval to Hutchison China MediTech Limited’s Sulanda (surufatinib) for non-pancreatic neuroendocrine tumors. The vascular endothelial growth factor receptor inhibitor is the second Chi-Med oncology drug to be approved in the country and the first launch for the company in the sector without a partnership.
In an earlier interview, CEO Christian Hogg had noted the Hong Kong-based company had grown its overall sales nearly 10-fold...








